[HTML] frontiersin.org

[HTML][HTML] The “old” and the “new” antibiotics for MDR gram-negative pathogens: for whom, when, and how

I Karaiskos, S Lagou, K Pontikis, V Rapti… - Frontiers in public …, 2019 - frontiersin.org
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …
被引用次数：284 相关文章
[PDF] redemc.net

[PDF][PDF] The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

I Karaiskos, S Lagou, K Pontikis, V Rapti, G Poulakou - cdn1.redemc.net
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …

The" Old" and the" New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How.

I Karaiskos, S Lagou, K Pontikis, V Rapti… - Frontiers in Public …, 2019 - europepmc.org
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …

[引用][C] The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

I Karaiskos, S Lagou, K Pontikis, V Rapti… - Frontiers in Public …, 2019 - cir.nii.ac.jp
The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When,
and How | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データを …
[PDF] scienceopen.com

[PDF][PDF] The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

I Karaiskos, S Lagou, K Pontikis, V Rapti, G Poulakou - scienceopen.com
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …
[PDF] redemc.net

[PDF][PDF] The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

I Karaiskos, S Lagou, K Pontikis, V Rapti, G Poulakou - redemc.net
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …

The" Old" and the" New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

I Karaiskos, S Lagou, K Pontikis… - Frontiers in public …, 2019 - pubmed.ncbi.nlm.nih.gov
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …
[HTML] frontiersin.org

[HTML][HTML] The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

I Karaiskos, S Lagou, K Pontikis, V Rapti… - Frontiers in Public …, 2019 - frontiersin.org
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …
[HTML] nih.gov

[HTML][HTML] The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

I Karaiskos, S Lagou, K Pontikis, V Rapti… - Frontiers in Public …, 2019 - ncbi.nlm.nih.gov
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …
[PDF] academia.edu

[PDF][PDF] The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

I Karaiskos, S Lagou, K Pontikis, V Rapti, G Poulakou - academia.edu
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …